ABCG2 and acute myeloid leukemia: P-gp, MRP1, MRP3 and BCRP activities have been shown to contribute to resistance to conventional cytarabine and anthracycline-based chemotherapy such as Daunorubicin, Idarubicin and Mitoxantrone in AML [13].